Data further validates the AnelloVector™ platform as the first gene delivery vector system based on the human commensal anellovirus CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ring ...
That therapy uses an adeno-associated virus (AAV) as a vector rather than a lentivirus, a vector type that features in approved gene therapies such as Roche's Luxturna and Novartis' Zolgensma.
AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today ...